

**Current Status of the Implication
of the Clinical Practice Pattern in
Hemodialysis Prescription in
Regular Hemodialysis Patients in
Egypt (Kafr El-Shikh)**

Protocol of Thesis

Submitted for partial fulfillment of Master
Degree
in Nephrology

By

Israa Basuoni Abbas

M.B.B.Ch. Alexandria University
Diploma of Internal Medicine Zagazig University

Under Supervision of

Prof. Dr. Adel Hussin Afifi

Professor of Internal Medicine and Nephrology
Faculty of Medicine - Ain Shams University

Dr. Essam Nour El-Din

Assistant professor of Internal Medicine and Nephrology
Faculty of Medicine - Ain Shams University

**Faculty of Medicine
Ain Shams University**

2015

**الوضع الحالي لأشكال الممارسة الإكلينيكية المتبعه
لوصفات الاستصفاء الدموى لدى مرضى
الاستصفاء الدموى فى مصر (محافظة كفر الشيخ)**

رسالة

توطئة للحصول على درجة الماجستير فى أمراض الكلى

مقدمة من

إسراء بسيونى عباس

بكالوريوس الطب والجراحة . جامعة الإسكندرية

دبلومة الباطنة العامة . جامعة الزقازيق

تحت إشراف

أ.د/ عادل حسين عفيفى

أستاذ أمراض الباطنة والكلى

كلية الطب - جامعة عين شمس

د. / عصام نور الدين عفيفى

أستاذ مساعد أمراض الباطنة والكلى

كلية الطب - جامعة عين شمس

كلية الطب

جامعة عين شمس

2015



First and foremost thanks to ALLAH, the Most Merciful.

*I wish to express my deep appreciation and sincere gratitude to **Prof Dr. Adel Afifi**, Professor of Internal Medicine and nephrology, Ain Shams University, for his close supervision, valuable instructions, continuous help, patience, advices and guidance. he has generously devoted much of his time and effort for planning and supervision of this study. It was a great honor to me to work under his direct supervision.*

*I wish to express my great thanks and gratitude to **Dr. Essam Nour ELdein**, assistant professor of Internal Medicine and nephrology, Ain Shams University, for her kind supervision, indispensable advice and great help in this work.*

Last and not least, I want to thank all my family, my colleagues, for their valuable help and support.

Finally I would present all my appreciations to my patients without them, this work could not have been completed.

Contents

Subject	Page
<i>List of abbreviations</i>	<i>II</i>
<i>List of tables</i>	<i>VII</i>
<i>List of figures</i>	<i>IX</i>
Introduction	1
Aim of the work	4
Review of literature	
Chapter (1): Hemodialysis as a renal replacement therapy.	5
Chapter (2): Regimens Of Hemodialysis	9
Chapter (3): Care of hemodialyses patients	23
Chapter (4): Dialysis Outcomes and Practice Patterns Study(DOPPS)	49
Chapter (5): End-stage renal disease (ESRD) in Egypt	63
Patients and methods	66
Results	71
Discussion	117
Summary &Conclusion	130
Recommendations	135
References	136
Arabic summary	-

List of Tables

Number	Name	page
Table (1)	Classification and characteristics of the various hemodialysis modalities	
Table (2)	Centers for Disease Control and Prevention. Recommended adult immunization schedule for United States 2011.	
Table (3)	Cost-Effective Cancer Screening in Dialysis Patients	
Table (4)	Gender distribution in the study population	
Table (5)	Different causes of ESRD in the study population	
Table (6)	Different co-morbidities in the study population: HTN	
Table (7)	Different co-morbidities in the study population: DM	
Table (8)	Different co-morbidities in the study population: IHD	
Table (9)	Different co-morbidities in the study population: CVS	
Table (10)	Different co-morbidities in the study population :PVD	
Table (11)	Different co-morbidities in the study population: CLD	
Table (12)	Different co-morbidities in the study population : COPD	
Table (13)	Different co-morbidities in the study population :Chronic Arthropathy	
Table (14)	Work status in the study population	
Table (15)	Dependency status in the study population	
Table (16)	Wheelchair status in the study population	
Table (17)	Frequency of HD sessions/week in the study population	
Table (18)	Duration of HD session in the study population	
Table (19)	Sponsoring status in the study population	
Table (20)	Types of vascular access in the study population	
Table (21)	Percent of access failure in the study population	
Table (22)	Frequency of access failure in the study population.	

Table (23)	The levels of Hemoglobin , Iron study during the last 6 months covered by the study.	
Table (24)	Hemoglobin category in the study population	
Table (25)	Ferritin levels in the study population.	
Table (26)	History of blood transfusion in the study population	
Table (27)	Different types of ESA used by the study population	
Table (28)	frequency of ESA brand used by the study population.	
Table (29)	Different ESA doses used in the study population	
Table (30)	History of iron injection in the study population	
Table (31)	History of vitamin B complex used in the study population	
Table (32)	History of L-Carnitine used in the study population	
Table (33)	The levels of Calcium, phosphorus ,Ca X po4 product and PTH during the last 6 months covered by the study	
Table (34)	Calcium levels in the study population	
Table (35)	Phosphorus level in the study population	
Table (36)	Calcium phosphorus product level in the study population.	
Table (37)	PTH levels in the study population	
Table (38)	Different types of phosphorus binders used by the study population.	
Table (39)	History of vitamin D used in the study population.	
Table (40)	Dose of vitamin D (calcitriol) used in the study population.	
Table (41)	Types of complications during HD session in the study population.	
Table (42)	Viral status in the study population	
Table (43)	Criteria of dialyzer model used in the study population	
Table (44)	dialyzer surface area used in the study population	
Table (45)	criteria of dialysate used in the study population.	

No	Title	Page
1	UK Registry definition of end-stage renal disease	6
2	Main causes of ESRD	9
3	Recommended dietary intake for chronic kidney and end-stage renal disease patients	30
4	The mean duration before need for RRT	32
5	Key Components of the HD Prescription	43
6	Quality measures in ESRD	67
7	QA components: domains suggested where monitoring quality measures may be of most importance	69
8	CPMs used to assess quality in a large dialysis service provider network	70
9	Hemodialysis Centers in Assiut city	82
10	the hemodialysis center data of the studied “patients, Machines, nursing staff, and doctors” in Assiut city	83
11	The Age of the study population	84
12	Gender Of the study population	85
13	Etiology of ESRD in the study population	86
14	Comorbidities in the study population	87
15	Dialysis Complications in the study population	89
16	Frequency of hemodialysis sessions/week in the study population	90
17	Dialysis duration in the study population (years)	91
18	Duration of HD session in the study population	91
19	Dependency and chair bound	92
20	work status in the study population	92
21	Sponsoring Status in the study population	93
List of Tables (cont.)		

22	Type of vascular access in the study population	94
23	the percentage of failed hemodialysis access in the study population	96
24	the number of hemodialysis access failures in the study population	96
25	Hemoglobin category in the study population	98
26	the treatment options for anemia in the study population	99
27	the dose of ESA used in the study population	100
28	L-Carnitine supplement	100
29	PO4 Binders	100
30	Vitamin D supplement	100
31	Vitamin D dose ug/wk	101
32	Calcimimetic (Cinacalcet) use	101
33	Hepatitis-C virus status of the study population	101
34	Isolation of HCV positive cases in the study population	102
35	HBV status in the study population	35
36	Isolation of HBV positive patients	104
37	HIV status in the study population	105
38	The dialyzer models used in the study population	105
39	Dialyzer material used in the study population	106
40	Dialyzer surface area used in the study population	107
41	Dialysate type used in the study population	108
42	Sterilization method used for the dialyzers	109
43	Dialysate bath used for patients	109
44	Anticoagulation type used in the study population	110
45	Anticoagulation dose used in the study population	110

List of Figures

No	Title	Page
1	Holistic approach to CKD based on the integration of hospital care and home care	16
2	OPTIMA treatment algorithm for “Early use of calcimimetics and reduced-dose vitamin D sterols”	23
3	Extracorporeal circuit	45
4	Typical concentrations of electrolytes in dialysis fluid	47
5	Dialysis fluid pathway in hemodialysis	49
6	Dialysis fluid pathway in post dilution hemodiafiltration	51
7	Consistent improvement of dialysis adequacy in a dialysis network which implemented a formal collection, analysis, and reporting of CPMs, including Kt/V	71
8	Hemodialysis Centers in Assiut city	82
9	HD center data of the studied “patients, Machines, nursing staff, and doctors”in Assiut city	84
10	The Age of study population	85
11	Gender Of the study population	86
12	Etiology of ESRD in the study population	87
13	Comorbidities percentage in the study population	88
14	Percentage of Dialysis Complications in the study population	89
15	Frequency of HD sessions/week in the study population	90
16	Duration of hemodialysis session in the study population	91
17	Dependency and chair bound	92

List of Figures (cont.)		
18	Work status in the study population	93
19	Sponsoring Status in the study population	94
20	The type of hemodialysis vascular access in the study population	95
21	The number of vascular access failure in the study population	97
22	Hemoglobin category in in the study population	98
23	the treatment options for anemia in the study population	99
24	Hepatitis-C virus status of the study population	102
25	Isolation of HCV positive cases in the study population	103
26	HBV status in the study population	104
27	The dialyzer models used in the study population	106
28	Dialyzer material used in the study population	107
29	Dialyzer surface area used in the study population	108
30	Dialysate type used in the study population	109
31	Anticoagulation dose used in the study population	111

INTRODUCTION

Studies examining the link between research evidence and clinical practice have consistently shown gaps between the evidence and current practice. Some studies in the United States suggest that 30%–40% of patients do not receive evidence-based care, while in 20% of patients care may be not needed or potentially harmful.¹ However, relatively little information exists about how to apply evidence in clinical practice, and data on the effect of evidence-based guidelines on knowledge uptake, process of care or patient outcomes is limited.

In recent years, specific clinical guidelines have been developed to optimize the quality of anemia management secondary to chronic kidney diseases(CKD).As a result, the National Kidney Foundation Kidney Disease Outcome Quality Initiative (K\DOQ I) guidelines and the Renal-European Dialysis and Transplantation Association best practice guidelines have been published in USA & Europe. Therefore; clinical practice guidance help individual physician and physicians as group to improve their clinical performance and thus raise standard of patient care towards optimum levels, They may also help to insure that all institution provide an equally good base line standard of care(*Cameron,1999*).

Introduction

Guidelines practiced on anemia and actual practices are much different with different places and patients according to treatment. Moreover, in individual countries and individual units within countries local circumstances relating to economic conditions; organization of health care delivery or even legal constraints may render the immediate implementation of best practice guidelines difficult or impossible. Nevertheless, they provide a goal against which progress can be measured (*Locatelli et al., 2004*).

Dialysis Outcomes and Practice Patterns Study (DOPPS) has observed a large variation in anemia management among different countries. The main hemoglobin concentration in hemodialysis patient varied widely across the studied countries ranging between 8g/dl to 11g/dl. The percentage of prevalent hemodialysis patient receiving erythropoietin stimulating agent 'ESA' has increased from 75% to 83%. The percentage of HD patient receiving iron varies greatly among DOPPS countries range from 38% to 89% (*Locatelli et al., 2004*).

There are challenges in implanting clinical guidelines in medical practice. Overall DOPPS data which show that, despite the availability of practice guidelines for treatment of renal anemia, wider variation in anemia management exists

Introduction

as gap between what is recommended by the guidelines and is accomplished in every day clinical practice. Compliance with clinical guidelines is an importance indicator of quality and efficacy of patient care at the same time their adaptation in clinical practice may be initiated by numerous factors including; clinical experts, patient performance, constrains of public health policies, community standard, budgetary limitation and methods of feeding back information concerning current practice (*Cameron,1999*).

AIM OF THE WORK

1. To study the pattern of current clinical practice in hemodialysis prescription in regular hemodialysis patients in Egypt and to compare this pattern with standard international guidelines in hemodialysis prescription (K/DIGO 2010), stressing on anemia, bone disease management and adequacy of dialysis.
2. Statement of the current status of dialysis patient in Egypt (questionnaire)

Chapter (1)

Hemodialysis as a renal replacement therapy.

Artificial support of the functions of failing organs has a history deeply rooted in the beginning of the last century. Although artificial respiration may have been used as early as Roman times by the physician *Galen*, and as late as 1908 by *George Poe*, support of the failing kidney began as early as 1913. Two scholars are credited repeatedly in the literature, *Dr. John J. Abel and Dr. W. J. Kolff*, as the forefathers of modern dialysis. “Vivi-diffusion” was coined in a paper given before the Association of American Physicians in 1913 in which the blood of animals was cleaned of intermediaries of metabolism. (*Abel JJ et al.,1990*).

This “vivi-diffusion” was achieved using arterial cannulation and hirudin anticoagulation in a dog with blood directed through branching glass tubing to reach a series of cellulose dialysis membranes and then back to a venous cannula. This concept was concomitantly developed by Dr. Kolff in the Netherlands and led to the first apparatus available